Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Support For Small Companies In AMR Space Is Crucial Now

Executive Summary

G7 countries should look to US PASTEUR Act For Inspiration On Pull Incentives for Antimicrobials

You may also be interested in...



French Consortium Pioneers New AMR Development Model

A new consortium that has won funding from the French government will focus on developing new treatments, diagnostics and surveillance and make sure that these approaches are properly valued by involving health economists in new drug development.

US PASTEUR Act Promises More Than Other National AMR Initiatives

PASTEUR Act in the US is the most promising initiative out there to address antimicrobial resistance.

Industry Calls For Canadian Pricing Guideline Consultation To Be Suspended

IMC, the R&D-based pharmaceutical industry association in Canada, says the guideline will “exacerbate an already unpredictable regulatory environment.”

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS145369

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel